Objective: To investigate the association between gene polymorphism of vesicular monoamine transporter type 2(VMAT2) and schizophrenia in Han Chinese population. Methods: 430 patients with schizophrenia and 470 age-sex matched controls were recruited from four mental health centers. All patients were diagnosed by two psychiatrists based on the Structured Clinical Interview for DSM Disorders (SCID). The ligase detection reactions (LDR) method was used to assess the polymorphism of the two SNPs (rs363371 and rs363324) of VMAT2. Results: No associations of two SNPs with schizophrenia was found. When we stratified males and females for the analysis, we found that that in the recessive model of rs363371, there was an obvious significant association between rs363371 and schizophrenia in males (OR=0.564, 95% CI=0.357–0.892, p=0.014) but not females. For the association between rs363324 and schizophrenia, no association was found in either males or females. No association was found when stratifying early-onset schizophrenia and late-onset schizophrenia. Conclusion Our findings indicate that both rs363371 and rs363324 were not associated with schizophrenia, while it seemed that the AA genotype of rs363371 plays a protective effect in male Chinese in developing schizophrenia.

Objective To elucidate the effect of cognitive functions on medication compliance of schizophrenia patients at stable phase, and provide clinical cognitive coping strategies to improve the medication compliance of schizophrenia patients. Methods Two hundred and thirty-eight schizophrenia patients at stable phase, admitted to psychiatry department of the 3rd affiliated hospital of Sun Yat-sen University from May 2017 to October 2017, and all study subjects were divided into without medication compliance group (the scores of medication compliance scale≤4, n=32) and medication compliance group (the scores of medication compliance scale>4, n=206) by Medication Adherence Rating Scale (MARS). MATRICS Consensus Cognitive Battery (MCCB) and Brief Psychiatric Rating Scale (BPRS) were used to evaluate the differences of cognitive performance and disease severity between groups. The factors influencing medication compliance of schizophrenia patients with stable phase were explored by multiple linear regression analysis. Results (1) The total scores of MCCB and it,s subscales scores (except for visual learning) of schizophrenia patients with medication compliance were higher than that of patients without medication compliance. The scores of symbol coding, spatial span and emotional intelligence ability in medication compliance group were significantly higher than those of patients without medication compliance (P<0.05). (2) Symbol coding (neurocognition ability), emotion management (social cognition ability), severity of illness, and antipsychotic drug dose were the independent influencing factors of medication compliance of schizophrenia patients with stable phase (P<0.05). Conclusion The medication compliance of schizophrenia patients with stable phase is not only affected by antipsychotics dose and severity of illness, but also affected by neurocognitive and social cognitive functions.